John Leonard, Intellia CEO
Intellia suggests ATTR amyloidosis gene editing treatment has over a year of durability as it gears up for PhIII
Intellia on Thursday presented new results for its gene editing treatment in 65 patients with ATTR amyloidosis — a condition in which …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
